和鉑醫藥(02142.HK)擬售蘇州生產廠房及相關資產 料錄虧損6,193萬元
和鉑醫藥-B(02142.HK)公布,和鉑醫藥(蘇州)以總代價1.46億元人民幣(下同),向藥明生物(02269.HK)旗下蘇州藥明海德生物科技出售有關生物大分子研發創新中心項目的生產廠房,包括機械及設備、各類車輛、工具及儀器、傢具、通信設施及設備、租賃場所內的固定裝置(包括賣方安裝的設備及設施)、有關生產廠房的辦公設備及傢具,以及有關生產廠房的相關協議的若干轉讓。
公司預期出售事項將錄虧損約6,193萬元。公司解釋出售事項旨在將在建資產變現,而由於出售事項後運營成本降低,公司可將其財務及其他資源重新分配至藥物開發,在擴大其他業務合作的同時將集團的平台價值最大化。
該生產廠房位於蘇州市工業園區新澤路1號生物醫藥產業園三期A區。集團擬與買方及其聯繫人建立長期戰略關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.